This study investigates the acceptability of artificial intelligence (AI) as a diagnostic support tool among patients with localized prostate cancer and healthcare providers, as well as their willingness to share health data for AI development. Background AI tools in healthcare show promising potential, especially in improving diagnosis accuracy and personalizing treatment. However, successful implementation depends not only on technical performance but also on the acceptability of AI among its users-both patients and professionals. Prior research has shown varied acceptability depending on context, disease severity, task performed by AI, and user population. Objectives Assess patients' acceptability of AI as a diagnostic support in prostate cancer. Explore patients' willingness to share health data for developing clinical AI. Assess healthcare providers' acceptability of AI in this diagnostic context. Methodology Design: A cross-sectional, mixed-method, multinational study (Belgium, Italy, Spain). Quantitative Phase: Online questionnaire, using adapted theoretical frameworks (Value Perception Model, NASSS-AI, TFA). Qualitative Phase: Will follow based on quantitative findings. Participants: Adults diagnosed with localized prostate cancer. Recruitment via hospitals, social media, and patient associations. Data Collected: Personal and health information, attitudes toward AI, willingness to share data. Ethics Approved by ethics committees in each participating country. Informed consent obtained digitally before participation. Data anonymized and GDPR-compliant.
Age range
18 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Perceived Benefits of using AI in the diagnosis of prostate cancer
Timeframe: Baseline
Perceived Risks of using AI in the prostate cancer diagnosis
Timeframe: Baseline
Intention to use AI
Timeframe: Baseline
Willingless to share personal data
Timeframe: Baseline